Dynavax Technologies Co. (DVAX) Expected to Post Quarterly Sales of $5.63 Million

Share on StockTwits

Analysts forecast that Dynavax Technologies Co. (NASDAQ:DVAX) will announce sales of $5.63 million for the current quarter, Zacks reports. Two analysts have provided estimates for Dynavax Technologies’ earnings. The highest sales estimate is $7.71 million and the lowest is $3.54 million. Dynavax Technologies reported sales of $20,000.00 during the same quarter last year, which would suggest a positive year over year growth rate of 28,050%. The firm is expected to report its next earnings results on Thursday, March 14th.

On average, analysts expect that Dynavax Technologies will report full year sales of $11.62 million for the current fiscal year, with estimates ranging from $7.96 million to $15.27 million. For the next fiscal year, analysts anticipate that the firm will report sales of $93.41 million, with estimates ranging from $88.23 million to $98.58 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Dynavax Technologies.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Dynavax Technologies had a negative net margin of 8,570.06% and a negative return on equity of 72.31%. The firm had revenue of $1.46 million for the quarter, compared to the consensus estimate of $3.16 million. During the same quarter in the prior year, the firm earned ($0.38) earnings per share. The company’s revenue was up 2822.0% on a year-over-year basis.

Several equities analysts recently issued reports on the company. Royal Bank of Canada lowered their price target on Dynavax Technologies from $26.00 to $25.00 and set an “outperform” rating on the stock in a research note on Tuesday. Cowen reiterated a “buy” rating and issued a $30.00 price objective on shares of Dynavax Technologies in a research note on Tuesday. ValuEngine lowered Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Monday, July 30th. BidaskClub upgraded Dynavax Technologies from a “strong sell” rating to a “sell” rating in a research note on Thursday, October 11th. Finally, Zacks Investment Research upgraded Dynavax Technologies from a “sell” rating to a “hold” rating in a research note on Tuesday, July 24th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $28.00.

DVAX traded up $0.42 on Friday, hitting $12.07. 1,366,998 shares of the stock traded hands, compared to its average volume of 1,381,619. Dynavax Technologies has a 52 week low of $9.63 and a 52 week high of $22.80. The company has a quick ratio of 8.67, a current ratio of 8.87 and a debt-to-equity ratio of 0.76. The firm has a market capitalization of $713.82 million, a price-to-earnings ratio of -6.98 and a beta of 0.61.

Several hedge funds have recently added to or reduced their stakes in DVAX. Gofen & Glossberg LLC IL bought a new stake in shares of Dynavax Technologies in the 3rd quarter valued at approximately $145,000. Tiverton Asset Management LLC bought a new stake in shares of Dynavax Technologies in the 2nd quarter valued at approximately $184,000. WINTON GROUP Ltd acquired a new position in shares of Dynavax Technologies in the 1st quarter worth approximately $199,000. Xact Kapitalforvaltning AB acquired a new position in shares of Dynavax Technologies in the 1st quarter worth approximately $200,000. Finally, Commonwealth Equity Services LLC acquired a new position in shares of Dynavax Technologies in the 1st quarter worth approximately $212,000. Institutional investors own 81.48% of the company’s stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.

Featured Article: How accurate is the Rule of 72?

Get a free copy of the Zacks research report on Dynavax Technologies (DVAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply